Clinical Trial Detail

NCT ID NCT03767335
Title MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer (B-PRECISE-01)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Menarini Group
Indications

breast adenocarcinoma

Therapies

CH5132799 + Fulvestrant + Trastuzumab

CH5132799 + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST